167159-95-7

Upstream product

• 54512-75-3 1-bromo-5-chloropentane 
• 167159-69-5 α-(Cyclohexylthio)-3,4-dimethoxybenzeneacetonitrile 
• 1569-69-3 Cyclohexanethiol 
• 28750-77-8 α-chloro-3,4-dimetoxybenzeneacetonitrile 

Downstream Products

• 167159-34-4 α-(Cyclohexylthio)-α-(3,4-dimethoxyphenyl)-3,4-dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolineheptanenitrile 
• 167159-27-5 a-(Cyclohexylthio)-α-(3,4-dimethoxyphenyl)-1,3-dioxo-2H-isoindole-2-heptanenitrile 
• 167159-35-5 7-(2-Chloroethoxy)-α-(cyclohexylthio)-α-(3,4-dimethoxyphenyl)-3,4-dihydro-6-methoxy-2(1H)-isoquinolineheptanonitrile 
• 167159-70-8 α-(5-aminopentyl)-α-(cyclohexylthio)-3,4-dimethoxybenzeneacetonitrile 

Relevant academic research and scientific papers

Novel multidrug resistance reversal agents

A series of 59 α-aryl-α-thioether-alkyl, -alkanenitrile, and - alkanecarboxylic acid methyl ester tetrahydroisoquinoline and isoindoline derivatives (15a-48) were synthesized and evaluated as multidrug resistance (MDR) reversal agents. The compounds were

MDR reversal agents

Compounds of the general formula: STR1 wherein R1, R2, R3, R4 and R5 are herein described, A is a straight or branched (C2 -C12)alkyl or a phenyl moiety and B is a moiety of the formula: STR2 The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.